DOWNLOAD A SUMMARY OF THE 11TH INTERNATIONAL CONFERENCE
European guidelines recommend treating HHV-6 disease with either foscarnet or ganciclovir, in contrast to the Japanese guidelines that recommend foscarnet as first line treatment due to a lower mortality rate.
After years of very little interest by the scientific community, there has suddenly been a lot of interest in HHV-6A, which along with HHV-7, appears to be central to the progression of Alzheimer’s disease.
Investigators from University of Michigan have demonstrated that murine roseolovirus is a useful homolog for the study of HHV-6 reactivation in lung disease. In a large retrospective study of HCT patients, they also found early HHV-6 reactivation to increase the risk of both idiopathic pneumonia syndrome and non-relapse mortality.
Newsletter | About Us | Contact Us | Donate | Repository